SpotLight

Within a three-day period, Phathom Pharmaceuticals achieves dual FDA approvals for Voquezna, its groundbreaking heartburn medication.

The evolving landscape of NSCLC treatment presents significant market opportunities for pharmaceutical companies to secure their place.

Rehabilitation equipment, a cornerstone in the realm of healthcare, has undergone a remarkable evolution over the years, propelled by the rising demand and their potential to improve patient outcomes and restore quality of life. From rudimentary tools and manual therapies to the present-day sophisticated, technolog...

Servier’s Tibsovo has received FDA approval for patients diagnosed with R/R myelodysplastic syndromes that exhibit an IDH1 mutation.

Roche’s Vabysmo secures new FDA nod for retinal vein occlusion treatment, intensifying competition with Regeneron and Bayer’s Eylea.

The Energy-Based Aesthetic Devices market stands at the forefront of the evolving landscape of cosmetic treatments, offering a comprehensive range of solutions for individuals seeking non-invasive and minimally invasive procedures to enhance their appearance. Over the past few years, intense advancements in technol...

Coherus and Junshi received FDA approval for Loqtorzi, marking significant milestone as first-ever nasopharyngeal carcinoma treatment.

The dynamics of the Niemann-Pick Disease Type C treatment market are expected to change owing to the emerging therapies by key companies.

Molecular modeling, a revolutionary branch of science that seeks to understand and manipulate the intricate world of molecules at the atomic and molecular levels, has seen a remarkable transformation in recent years, owing to the growth in technology. The union of computational science, chemistry, and biology has g...

There are several bone sarcoma types, originating from different cells within bone structure and require specialized diagnosis and treatment